Table 2.

Univariate and multivariate analyses of overall survival (OS).

		Univariate				Multivariate
Variable	Category	HR	Lower	Upper	P-value*	HR	Lower	Upper	P-value*
Treatment	Cohort A vs. cohort B	0.48	0.40	0.59	<0.001	0.58	0.47	0.72	<0.001
Age	≥65 vs. <65	1.22	1.01	1.48	0.044	1.17	0.96	1.43	0.127
Gender	Male vs. Female	0.95	0.79	1.16	0.634
Body mass index	<18.5 kg/m2 vs. ≥18.5	0.94	0.72	1.22	0.623
ECOG PS	1 or 2 vs. 0	1.64	1.35	2.01	<0.001	1.44	1.16	1.78	0.001
Primary tumor site	Left vs. Right	0.79	0.63	0.99	0.042	0.88	0.69	1.13	0.315
Surgery on primary tumor site	Yes vs. No	0.60	0.48	0.76	<0.001	0.80	0.62	1.02	0.071
Pathologic type	Well-moderately differentiated vs. others	0.97	0.64	1.46	0.874
Baseline serum albumin	>3.5 g/dL vs. <3.5	0.51	0.43	0.62	<0.001	0.77	0.63	0.94	0.012
Baseline serum AST	≥40 IU/L vs. <40	1.84	1.53	2.22	<0.001	1.48	1.24	1.76	<0.001
Baseline serum CRP	≥1.0 mg/dL vs. <1.0	1.68	1.44	1.95	<0.001	1.84	1.46	2.32	<0.001
Baseline serum CEA	≥5 ng/mL vs. <5	1.85	1.38	2.49	<0.001	1.69	1.16	2.47	0.006
Liver metastasis	Yes vs. No	1.65	1.35	2.03	<0.001	1.51	1.17	1.94	0.001
Lung metastasis	Yes vs. No	0.84	0.69	1.03	0.089	0.95	0.75	1.49	0.691
Lymph node metastasis	Yes vs. No	1.40	1.15	1.70	<0.001	1.18	0.94	1.49	0.150
Peritoneal dissemination	Yes vs. No	1.52	1.20	1.93	<0.001	1.38	1.05	1.82	0.023
Bone	Yes vs. No	0.96	0.70	1.34	0.829
Number of metastatic organ sites	≥2 vs. 1	1.48	1.18	1.87	0.001	1.05	0.76	1.43	0.777
Prior regimens	≥3 vs. <3	0.85	0.70	1.04	0.108	0.79	0.61	1.03	0.078
Time since initiation of first-line chemotherapy	≥18 months vs. <18	0.63	0.51	0.78	<0.001	0.64	0.50	0.81	<0.001
RAS status	MT vs. WT	1.18	0.99	1.41	0.067	0.91	0.71	1.16	0.455

^*P-values were calculated using the Cox proportional-hazards model.

RAS, rat sarcoma; AST, aspartate transaminase; CEA, carcinoembryonic antigen; WT, wild-type; MT, mutant.